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Abstract
We investigated whether growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 (MIC-
1), levels are associated with a prothrombotic state in atrial fibrillation (AF) as compared to N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) and high-sensitivity cardiac troponin I (cTnI-hs). In 103 patients with AF assessed off anticoagula-
tion (age: 71.0 [65.0–76.0] years;  CHA2DS2-VASc score: 4.6 ± 1.7), we measured endogenous thrombin potential (ETP), 
plasma fibrin clot permeability (Ks, a measure of clot density) and clot lysis time (CLT) and other hemostatic parameters, 
along with GDF-15, NT-proBNP, and cTnI-hs. GDF-15 positively correlated with ETP and CLT (r = 0.25, P = 0.01 and 
R = 0.56, P < 0.0001, respectively) but not with Ks, von Willebrand factor, thrombin-activatable fibrinolysis inhibitor, plas-
minogen, antiplasmin or tissue-type plasminogen activator antigen. NT-proBNP showed a stronger association with ETP 
(r = 0.60, P < 0.0001) and a similar correlation with CLT (R = 0.53, P < 0.0001), while cTnI-hs correlated solely with CLT 
(R = 0.25, P = 0.01). After adjustment for clinical and laboratory parameters, GDF-15 was a better independent predictor of 
CLT (unstandardized coefficient B 0.009; 95% confidence interval [CI] 0.006–0.012) than NT-proBNP (B 0.007; 95% CI 
0.004–0.010, R (2) = 0.51; P < 0.0001); while among the three biomarkers, only NT-proBNP was an independent predictor 
of ETP. Elevated GDF-15 and NT-proBNP independently predict impaired fibrin clot lysability, while NT-proBNP is a key 
predictor of heightened thrombin formation in AF. Our findings suggest that a predictive value of NT-proBNP and GDF-15 
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Introduction
Atrial fibrillation (AF) increases the risk of stroke and sys-
temic thromboembolism. Their current prediction scores are 
based on clinical variables. Increasing amount of data indi-
cates the potential of cardiac biomarkers to improve predic-
tion of outcomes in patients with AF [1, 2]. Recently, in AF 
N-terminal pro-B-type natriuretic peptide (NT-proBNP) and 
high-sensitivity cardiac troponin (cTn-hs) have been shown 
to be strong and independent predictors of thromboembo-
lism and when combined with clinical data, improve stroke 
risk assessment [3, 4]. Moreover, the two biomarkers have 
been reported to be associated with a prothrombotic state in 
AF [5, 6]. In addition, in patients with AF on anticoagula-
tion, NT-proBNP was not an independent predictor of major 
bleeding [7, 8].
Growth differentiation factor-15 (GDF-15), also known 
as macrophage inhibitory cytokine-1 (MIC-1), along with 
NT-proBNP, cTn-hs, age and heart failure diagnosis, have 
been reported to predict death in AF [9]. GDF-15 in anti-
coagulated patients with AF has been found to be strongly 
associated with increased risk of major bleeding, indepen-
dently of cardiovascular risk factors and other biomarkers, 
but only in these complex models, it was not associated with 
stroke/systemic embolism risk [8, 10–12]. Moreover, there is 
evidence linking GDF-15 with left atrial/left atrial append-
age thrombus presence in AF [13].
Mechanisms linking GDF-15 with thromboembolism in 
AF are unknown. We investigated the relationship between 
GDF-15 with prothrombotic abnormalities in AF patients 
compared with NT-proBNP and high-sensitivity cardiac 
troponin I (cTnI-hs).
Methods
In a cross-sectional study, we evaluated patients with AF. We 
excluded individuals with myocardial infarction or venous 
thromboembolism within the previous 3 months, kidney fail-
ure requiring dialysis or creatinine clearance < 15 mL/min, 
liver cirrhosis, known cancer and acute infection. Comor-
bidities and clinical scores were assessed as described [5, 6]. 
The study protocol was approved by bioethical committee 
and all patients gave informed consent to participate in the 
study.
Demographic and clinical data were collected at enrol-
ment. Conventional techniques were used to perform tran-
sthoracic echocardiography. Fasting venous blood sam-
ples were collected in patients off oral anticoagulation. In 
patients on oral anticoagulants, who were switched to low-
molecular-weight heparin, blood collection was performed 
after at least 12 h since the last heparin injection. None of 
the patients received anticoagulation treatment on the day 
of the study, as reported previously [5]. Apart from rou-
tine laboratory investigations, electrochemiluminescence 
immunoassays (Roche Diagnostics, Mannheim, Germany) 
were used to measure GDF-15 and NT-proBNP levels. 
Serum concentrations of cTnI-hs were determined using the 
ARCHITECT i1000SR (Abbott Laboratories, Abbott Park, 
IL, USA). Latex immunoassay using a STAR coagulation 
instrument (Diagnostica Stago, Asnières, France) was used 
to measure von Willebrand factor (vWF) antigen. Plasma 
tissue-type plasminogen activator (tPA), plasminogen acti-
vator inhibitor-1 (PAI-1) antigen and thrombin-activatable 
fibrinolysis inhibitor (TAFI) antigen were measured by ELI-
SAs (American Diagnostica, Stamford, Connecticut, USA 
and Chromogenix, Lexington, Massachusetts, USA). Anti-
plasmin and plasminogen were determined using chromog-
enic assays (Diagnostica Stago).
Measurement of endogenous thrombin potential (ETP) 
was performed using calibrated automated thrombography 
(CAT; Thrombinoscope BV, Maastricht, the Netherlands) 
in a 96-well plate fluorometer (Ascent Reader, Thermolat 
Systems OY, Helsinki, Finland) at 37 °C, as previously 
described [5, 14, 15]. Briefly, 80 µL of platelet-poor plasma 
was diluted with 20 µL of tissue factor (TF)-based activa-
tor (Diagnostica Stago, Asnières, France) containing 5 pmol 
 L−1 recombinant TF, 4 micromolar phosphatidylserine/
phosphatidylcholine/phosphatidylethanolamine vesicles 
and FluCa solution (20 µL; HEPES, pH 7.35, 100 nmol 
 L−1  CaCl2, 60 mg mL−1 bovine albumin and 2.5 mmol  L−1 
Z–Gly–Gly–Arg-amidometylcoumarin). ETP was measured 
twice [16].
The pore size in fiber networks is indicated by clot perme-
ability. It is proportional to a volume of buffer percolating 
through a clot under a specific hydrostatic pressure. Assess-
ment of clot permeability was described previously in detail 
[5, 17]. Briefly, 20 mmol/L calcium chloride and 1 U/mL 
of human thrombin (Sigma) were added to citrated plasma. 
Tubes with clots were joined with a reservoir of Tris-buff-
ered saline (0.1 mol/L NaCl, 0.01 mol/L Tris, pH 7.5). The 
volume flowing for 60 min through the gels was measured. 
The average size of fiber network pores is reflected by the 
permeation coefficient (Ks). Ks was calculated using the fol-
lowing equation: 
 where Q is the flow rate in time, L is the length of a fibrin 
gel, ƞ is the viscosity of liquid in poise, t is percolating time, 
Ks = Q × L × ∕t × A × Δp,
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A is the cross-sectional area in  cm2, Δp is a differential pres-
sure in dyne/cm2.
The turbidity method was used to determine plasma clot 
lysis time (CLT), as described previously [5, 17]. Briefly, cit-
rated plasma was mixed with 15 mmol/L calcium chloride, 
human tissue factor (10,000-diluted; Innovin, Siemens) at 
a final concentration of 0.6 pmol/L, phospholipid vesicles 
(12 µmol/L) and recombinant tPA (60 ng/mL; Boehringer 
Ingelheim, Ingelheim, Germany). Measurements were 
performed at 405 nm at 37 °C. The midpoint of the clear-
to-maximum-turbid transition indicated clot formation. 
Therefore, measurement from this time to the midpoint of 
the maximum-turbid-to-clear transition was defined as CLT.
Continuous variables were expressed as the mean ± stand-
ard deviation or median (interquartile range). Normality was 
assessed using the Shapiro–Wilk test. We stratified patients 
by median GDF-15 level into two groups, i.e., below (low 
GDF-15) and above or equal to the median of GDF-15 level 
(high GDF-15). Continuous variables were compared using 
Student t test or Mann–Whitney U test, as appropriate. Cor-
relations were tested using a linear Pearson correlation or 
Spearman rang test, as appropriate. Categorical variables 
were described by number (frequency) and compared by 
Pearson 2 test or Fisher’s exact test (if more than 20% of the 
cells had an expected count of less than 5 and/or if minimum 
expected count in the particular table was less than 1) [18]. 
To assess predictors of ETP and CLT, we performed linear 
regression analysis. R2 was calculated, and model adequacy 
assessment using F test was performed. P values < 0.05 were 
considered statistically significant. All statistical analyses 
were performed with IBM SPSS Statistics (version 24).
Results
The study group included 103 patients (women, 
44.7%; median age 71 [65–76] years) with the mean 
 CHA2DS2-VASc score of 4.6 ± 1.7 (Table 1). Ninety-nine 
patients (96.1%) had at least two additional (beyond sex) 
clinical stroke risk factors. The median GDF-15 was 1661.0 
(1094.0–2417.0) pg/mL. GDF-15 correlated with age 
and body mass index (R = 0.25, P = 0.01 and R = − 0.24, 
P = 0.01, respectively), but not with sex or  CHA2DS2-VASc 
score. Patients with high GDF-15 (≥ 1661.0 pg/mL) did 
not differ from the remaining subjects with regard to the 
type of AF, comorbidities or medications used except for 
lower prevalence of diabetes and lower use of torasem-
ide in the former group (Table 1). However, patients with 
diabetes mellitus, those using oral hypoglycemic drug 
or insulin did not differ from the remainder with regards 
to GDF-15 level (1491.0 [1075.0–1861.0] vs. 1727.0 
[1073.3–2452.5] pg/mL, P = 0.30; 1526.0 [1042.0–1867.5] 
vs. 1705.0 [1094.0–2449.0] pg/mL, P = 0.49 and 1415.0 
[940.8–2586.5] vs. 1684.0 [1129.3–2425.0] pg/mL, 
P = 0.61, respectively). We observed a trend towards inverse 
correlation between glomerular filtration rate (GFR) and 
GDF-15 (R = − 0.14, P = 0.16). Lower fibrinogen and glu-
cose levels were found in patients with high GDF-15, while 
high-density lipoprotein cholesterol was higher in this group 
(Supplementary Table S1). GDF-15 tended to inversely cor-
relate with white blood cell count (R = − 0.17; P = 0.08) and 
correlated with NT-proBNP (R = 0.27, P = 0.006) and cTnI-
hs (R = 0.28, P = 0.004).
Analysis of thrombin generation showed that there is a 
weak positive association of GDF-15 with ETP (r = 0.25, 
P = 0.01; Table 2). ETP strongly correlated with NT-proBNP 
(r = 0.60; P < 0.0001) and tended to correlate with cTnI-hs 
(r = 0.19, P = 0.05). On linear regression analysis, NT-
proBNP (standardized coefficient β 0.60; unstandardized 
coefficient B 0.08; 95% confidence interval [CI] 0.06–0.10, 
R2  = 0.36; P < 0.0001) and GDF-15 (β 0.25; B 0.03; 95% CI 
0.008–0.060, R2 = 0.06; P = 0.01), but not cTnI-hs (β 0.19; 
B 11.12; 95% CI − 0.12–22.35, R2 = 0.04; P = 0.052) pre-
dicted ETP. However, when NT-proBNP and GDF-15 were 
assessed together as predictors of ETP, only NT-proBNP 
remained a significant predictor (Supplementary Table S2). 
The same was true after adjustment for age, sex, BMI and 
fibrinogen (Supplementary Table 3) as well as after addi-
tional adjustment for coronary artery disease, heart failure/
left ventricular dysfunction, GFR, antiplasmin, PAI-1, TAFI, 
C-reactive protein (CRP) and cTnI-hs (Table 3).
As expected, Ks correlated with CLT (r = − 0.37, 
P = 0.001) and fibrinogen (r = − 0.49; P < 0.0001), but 
was not significantly  associated with other cardiovascu-
lar biomarkers or fibrinolysis parameters (only trends were 
observed, data not shown). However, Ks was inversely 
correlated with white blood cell count and CRP (for both 
r = − 0.25; P = 0.01).
Regarding fibrinolysis, GDF-15 showed no association 
with TAFI, plasminogen, antiplasmin, tPA or PAI-1 antigen 
(data not shown). GDF-15 correlated with CLT (R = 0.56, 
P < 0.0001; Fig. 1), but not with Ks (r = 0.01, P = 0.89). 
Patients with high GDF-15 had 19.2% longer CLT (Table 2). 
NT-proBNP correlated with CLT (R = 0.53, P < 0.0001), 
and tended to correlate with Ks (r = − 0.17, P = 0.10), while 
cTnI-hs showed weak association with CLT (R = 0.25, 
P = 0.01). Moreover, CLT correlated with ETP (r = 0.36, 
P = 0.0002). There was a trend towards correlation between 
CLT and  CHA2DS2-VASc score (R = 0.18, P = 0.07), without 
association with age or BMI (data not shown).
CLT was predicted by GDF-15 (β 0.57; B 0.011; 95% 
CI 0.008–0.014; R2 = 0.33; P < 0.0001), NT-proBNP (β 
0.51; B 0.009; 95% CI 0.006–0.012), R2 = 0.26; P < 0.0001) 
and cTnI-hs (β 0.23; B 1.84; 95% CI 0.29–3.39, R2 = 0.05; 
P = 0.02). In a model incorporating these three biomarkers, 
both GDF-15 and NT-proBNP, but not cTnI-hs, predicted 
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Table 1  Patient characteristics stratified by median GDF-15 level
Data are presented as mean ± standard deviation or median (interquartile range) or number (percentage)
ACE-I angiotensin-converting enzyme inhibitor, AF atrial fibrillation, ARB angiotensin II receptor blocker, BMI body mass index, CAD coronary 
artery disease, CCB calcium channel blocker, CKD chronic kidney disease, CLT clot lysis time, COPD chronic obstructive pulmonary disease, 
CVD cardiovascular disease, GDF-15 growth differentiation factor-15, LA left atrial, LVD left ventricular dysfunction, LVEF left ventricular 
ejection fraction, MI myocardial infarction, n number
*Fisher’s exact test (exact significance, 2-sided)
a The data for LVEF and LA diameter were available for 101 and 95 patients, respectively
Variable Whole group, n = 103 Low GDF-15 (445.3–1628.0 pg/
mL, n = 51)
High GDF-15 (1661.0–5163.0 pg/
mL, n = 52)
P value
Demographics
 Age (years) 71.0 (65.0–76.0) 69.0 (64.0–75.0) 73.0 (68.0–78.0) 0.01
 Male sex, n (%) 57 (55.3) 29 (56.9) 28 (53.8) 0.76
 BMI (kg/m2) 28.4 (25.5–32.4) 30.2 (26.5–33.9) 27.2 (25.0–30.3) 0.004
Type of AF
 Paroxysmal AF, n (%) 45 (43.7) 20 (39.2) 25 (48.1) 0.61
 Persistent AF, n (%) 22 (21.4) 11 (21.6) 11 (21.2)
 Permanent AF, n (%) 36 (35.0) 20 (39.2) 16 (30.8)
AF on the day of blood collection, 
n (%)
70 (68.0) 37 (72.5) 33 (63.5) 0.32
 CAD, n (%) 53 (51.5) 28 (54.9) 25 (48.1) 0.49
 COPD, n (%) 11 (10.7) 5 (9.8) 6 (11.5) 0.78
Comorbidities and CVD risk factors
 Hypertension, n (%) 85 (82.5) 43 (84.3) 42 (80.8) 0.64
 Diabetes mellitus, n (%) 41 (39.8) 26 (51.0) 15 (28.8) 0.02
 Dyslipidemia, n (%) 88 (85.4) 47 (92.2) 41 (78.8) 0.06
 Smoking history, n (%) 37 (35.9) 15 (29.4) 22 (42.3) 0.17
 Previous MI, n (%) 25 (24.3) 14 (27.5) 11 (21.2) 0.46
 Heart failure/LVD, n (%) 75 (72.8) 38 (74.5) 37 (71.2) 0.15
 Previous stroke, n (%) 14 (13.6) 5 (9.8) 9 (17.3) 0.27
 CKD stage 3 or 4, n (%) 29 (28.2) 15 (29.4) 14 (26.9) 0.78
 CHA2DS2-VASc score 4.6 ± 1.7 4.5 ± 1.9 4.6 ± 1.6 0.71
 HAS-BLED score 2 (1–2) 2.0 (1.0–2.0) 2.0 (1.0–2.0) 0.31
Medications, n (%)
 Beta-blocker 83 (80.6) 44 (86.3) 39 (75.0) 0.15
 ACE-I 63 (61.2) 32 (62.7) 31 (59.6) 0.75
 ARB 16 (15.5) 11 (21.6) 5 (9.6) 0.09
 CCB 20 (19.4) 12 (23.5) 8 (15.4) 0.30
 Aspirin 32 (31.1) 17 (33.3) 15 (28.8) 0.62
 Clopidogrel 5 (4.9) 3 (5.9) 2 (3.8) 0.68*
 Statin 75 (72.8) 37 (72.5) 38 (73.1) 0.95
 Digoxin 20 (19.4) 6 (11.8) 14 (26.9) 0.05
 Amiodarone 13 (12.6) 6 (11.8) 7 (13.5) 0.80
 Propafenone 9 (8.7) 6 (11.8) 3 (5.8) 0.32*
 Oral hypoglycemic drug 28 (27.2) 17 (33.3) 11 (21.2) 0.17
 Insulin 9 (8.7) 6 (11.8) 3 (5.8) 0.32*
 Aldosterone antagonist 26 (25.2) 17 (33.3) 9 (17.3) 0.06
 Furosemide 21 (20.4) 10 (19.6) 11 (21.2) 0.85
 Torasemide 26 (25.2) 18 (35.3) 8 (15.4) 0.02
 Hydrochlorothiazide 11 (10.7) 3 (5.9) 8 (15.4) 0.12
 Indapamide 17 (16.5) 11 (21.6) 6 (11.5) 0.17
Echocardiographic  parametersa
 LVEF (%) 47.7 ± 13.2 48.4 ± 14.6 47.0 ± 11.9 0.59
 LVEF ≥ 50%, n (%) 40 (39.6) 22 (44.0) 18 (35.3) 0.80
 LA diameter (cm) 4.6 (4.1–5.0) 4.4 (4.1–5.0) 4.7 (4.1–5.0) 0.33
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CLT (data not shown). GDF-15 and NT-proBNP predicted 
CLT in unadjusted model (Supplementary Table S2), after 
adjustment for age, sex, BMI and fibrinogen (Supplementary 
Table 3) as well as after additional adjustment for coronary 
artery disease, heart failure/left ventricular dysfunction, 
GFR, antiplasmin, PAI-1, TAFI, CRP, cTnI-hs (Table 3).
In our cohort vWF, a marker of endothelial dysfunction, 
showed a weak association with CLT (R = 0.24; P = 0.01), 
but was not related to the three biomarkers or fibrinolysis 
parameters (data not shown).
A median of mean heart rate was 75 (70–80) bpm. There 
was no correlation between Ks and CLT and mean heart 
rate (r = 0.03, P = 0.77 and R = − 0.03, P = 0.78, respec-
tively). On the day of blood collection, AF was observed in 
68.0% of patients (Table 1). There was no difference in Ks 
in patients with and without AF on the day of blood collec-
tion (6.7 ± 0.9 × 10−9  cm2 vs. 6.5 ± 0.8 × 10−9  cm2; P = 0.42). 
Table 2  Laboratory, coagulation and fibrinolysis parameters stratified by median GDF-15 level
Data are presented as mean ± standard deviation or median (interquartile range)
APTT activated partial thromboplastin time, CLT clot lysis time, CRP C-reactive protein, cTnI-hs high-sensitivity cardiac troponin I, ETP endog-
enous thrombin potential, GFR glomerular filtration rate, INR international normalized ratio, Ks clot permeability, NT-proBNP N-terminal pro-
B-type natriuretic peptide, PAI-1 plasminogen activator inhibitor-1, TAFI thrombin-activatable fibrinolysis inhibitor, tPA tissue-type plasmino-
gen activator, vWF von Willebrand factor For other abbreviations see Table 1
*The data for fibrinogen and cTnI-hs were available for 101 patients, while the data for CRP were available for 100 patients
Variable Whole group, n = 103 Low GDF-15 (445.3–1628.0 pg/
mL, n = 51)
High GDF-15 (1661.0–
5163.0 pg/mL, n = 52)
P value
Laboratory parameters
 GFR (mL/min) 73.0 (56.0–85.0) 74.0 (56.0–85.0) 73.0 (53.0–85.3) 0.70
 CRP (mg/L)* 1.7 (1.0–3.4) 1.7 (1.0–3.2) 1.6 (1.0–3.6) 0.73
 GDF-15 (pg/mL) 1661.0 (1094.0–2417.0) 1094.0 (834.2–1413.0) 2407.0 (1830.0–3175.8) < 0.0001
 NT-proBNP
(pg/mL)
721.0 (401.0–1396.0) 634.0 (440.0–1009.0) 1086.5 (398.8–1694.5) 0.09
 cTnI-hs (ng/l) 6.1 (5.0–7.5) 5.7 (4.6–7.1) 6.4 (5.5–8.3) 0.0099
Coagulation and fibrinolysis parameters
 APTT (s) 27.8 ± 3.8 27.5 ± 4.3 28.0 ± 3.2 0.48
 INR 1.0 (1.0–1.1) 1.1 (1.0–1.1) 1.0 (1.0–1.1) 0.45
 Fibrinogen (g/l)* 3.4 (2.7–4.1) 3.7 (3.2–4.0) 3.2 (2.4–4.1) 0.047
 vWF:Ag (%) 187.0 (151.0–234.0) 183.0 (135.0–220.0) 190.0 (155.8–243.8) 0.22
 TAFI:Ag (%) 102.0 (94.0–113.0) 105.0 (95.0–113.0) 100.0 (91.0–114.5) 0.51
 Plasminogen (%) 105.6 ± 14.3 103.7 ± 12.5 107.4 ± 15.7 0.19
 Antiplasmin (%) 106.0 (96.0–115.0) 107.0 (96.0–117.0) 103.5 (95.0–114.0) 0.70
 tPA:Ag (ng/mL) 7.2 (5.7–9.8) 7.0 (5.9–8.0) 7.6 (5.5–10.3) 0.49
 PAI-1:Ag (ng/mL) 15.6 ± 4.0 15.4 ± 3.8 15.8 ± 4.3 0.67
 ETP (nM × min) 1488.0 (1403.0–1578.0) 1453.0 (1374.0–1521.0) 1502.5 (1447.8–1610.3) 0.01
 Ks (× 10−9  cm2) 6.6 ± 0.9 6.6 ± 0.9 6.6 ± 0.9 0.69
 CLT (min) 98.0 (81.0–109.0) 86.0 (76.0–100.0) 102.5 (94.3–117.5) < 0.0001
Table 3  Multiple regression 
analysis of predictors of ETP 
and CLT in patients with atrial 
fibrillation
*Adjusted for age, sex, BMI, CAD, heart failure/LVD, GFR, antiplasmin, PAI-1, TAFI, CRP, cTnI-hs and 




Β (95% confidence interval)
P value
ETP ( R2 = 0.40; P < 0.0001)*
 NT-proBNP (pg/mL) 0.56 0.07 (0.05–0.10) <0.0001
 GDF-15 (pg/mL) 0.10 0.01 (− 0.01–0.04) 0.29
CLT ( R2 = 0.51; P < 0.0001)*
 NT-proBNP (pg/mL) 0.37 0.007 (0.004–0.010) <0.0001
 GDF-15 (pg/mL) 0.49 0.009 (0.006–0.012) <0.0001
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However, there was a tendency towards prolonged CLT (99.0 
[83.8–111.3] min vs. 91.0 [78.5–104.5] min; P = 0.12) and 
increased ETP (1495.5 [1433.3–1582.0] nM × min vs. 
1450.0 [1327.0–1541.5] nM × min; P = 0.08) in patients 
with AF on the day of blood collection, when compared 
with the remainder.
Discussion
The present study shows that in nonanticoagulated patients 
with AF, GDF-15 and NT-proBNP, after adjustment for 
clinical and laboratory parameters, are the independent 
predictors of prolonged clot lysis, a measure of plasma 
fibrinolytic potential. Only NT-proBNP has been observed 
to independently predict ETP, which suggests that these 
biomarkers may reflect various aspects of prothrombotic 
alterations observed in AF. Importantly, this study sup-
ports the evidence that elevated biomarkers in AF indicate 
higher thrombotic risk that cannot be fully explained by 
age or  CHA2DS2-VASc score. Our findings suggest that a 
predictive value of the two biomarkers in AF could be in 
part attributed to their association with prothrombotic blood 
alterations. However, mechanisms which underlie associa-
tions between these biomarkers and thrombotic tendency 
remain to be established.
We extend our previous observations on associations of 
NT-proBNP with CLT and ETP [5]. Here, we have shown 
that associations of NT-proBNP with these surrogate mark-
ers of a prothrombotic state are independent of other clinical 
and laboratory parameters as well as other biomarkers stud-
ied (including cTnI-hs and GDF-15). These data might help 
to explain observations that NT-proBNP is strongly linked to 
increased risk of stroke/systemic embolism independently of 
clinical risk factors and cTn-hs [4], but is not independently 
associated with major bleeding in AF [7, 8].
To our knowledge, there have been no published reports 
linking GDF-15 levels in circulating blood with specific 
hemostatic markers in AF, despite the fact that several stud-
ies demonstrated that elevated GDF-15 in AF is linked to 
increased risk of major bleeding, independently of cardio-
vascular risk factors and other biomarkers [10, 11]. Some 
investigators reported an increased risk of stroke or systemic 
embolism at elevated GDF-15 concentrations in AF patients 
even on oral anticoagulation [7]. However, a predictive role 
of GDF-15 in terms of stroke/systemic embolism remains 
still controversial as evidenced in models when other bio-
markers were included, namely NT-proBNP and cardiac 
troponin T in the Randomized Evaluation of Long-Term 
Anticoagulation Therapy (RE-LY) biomarker substudy and 
NT-proBNP, cardiac troponin I and cystatin C in the Apixa-
ban for Reduction in Stroke and Other Thromboembolic 
Events in Atrial Fibrillation (ARISTOTLE) trial substudy 
[8, 10, 11]. In these seminal trials, when multivariable analy-
ses including other biomarkers were performed, GDF-15 
was no longer independently associated with stroke/systemic 
embolism [8, 10, 11]. Expression of GDF-15 is induced by 
pro-inflammatory cytokines, including tumor necrosis fac-
tor (TNF)-α, interleukin (IL)-1β and IL-6 [19, 20]. GDF-
15 exerts anti-inflammatory effects, leading to inhibition 
of lipopolysaccharide-stimulated secretion of TNF-α by 
macrophages [19]. Moreover, GDF-15 has been shown to 
inhibit the activation of β1 and β2-integrins on platelets 
and prevent thrombus formation in mice, with no effect on 
platelet P-selectin expression and dense granule secretion 
after stimulation [21]. We observed that GDF-15 tended to 
inversely correlate with white blood cell count, but we did 
not find any association of GDF-15 with CRP with even 
lower fibrinogen at high GDF-15 concentrations, indicating 
the involvement of proinflammatory mechanisms independ-
ent of IL-6. We did not observe relations between GDF-15 
and vWF, tPA, or PAI-1 antigen in our patients with AF. 
However, in a cohort of elderly patients GDF-15 was found 
to be weakly or moderately related to vWF, PAI-1 activity 
and tPA antigen, suggesting that in patients with AF, GDF-
15 may reflect other prothrombotic alterations [22].
Our key observation reported here is a positive associa-
tion between GDF-15 and CLT, indicating that processes 
leading to elevation of GDF-15 drive antifibrinolytic reac-
tions unrelated to increased PAI-1 or antiplasmin. A weak 
association between GDF-15 and lysis time observed in 
univariate analysis has been recently reported in patients 
after acute coronary syndrome (ACS) included in the 
PLATelet inhibition and patient Outcomes (PLATO) 
Fig. 1  Correlation of clot lysis time (CLT) with growth differentiation 
factor-15 (GDF-15) in patients with atrial fibrillation
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trial [23]. It might be speculated that oxidative stress and 
inflammation [5, 24, 25] promote both elevation of GDF-
15 and prothrombotic alterations, rendering both GDF-15 
and CLT potentially valuable markers both in AF and after 
ACS.
It has been shown that formation of denser fibrin clots 
is associated with increased risk of thromboembolism in 
patients with AF on oral anticoagulation [26, 27]. Given 
an inverse association between clot permeability and CLT, 
it is possible that CLT has a similar prognostic value. In 
the light of the available data, associations between clini-
cal outcomes and the biomarkers tested are complex. It 
remains to be explored in a large prospective cohort study 
whether a predictive value of GDF-15 in terms of morbid-
ity and mortality in AF [7, 9, 10, 13] is in part mediated 
by suppressed plasma fibrinolytic potential. The independ-
ent association of NT-proBNP with both increased ETP 
and prolonged CLT is consistent with clinical findings 
indicating that NT-proBNP is more potent than GDF-15 
predictor of thromboembolic risk in AF [8]. Our results 
support the evolving use of biomarkers in more individu-
alized patient-oriented thromboembolic risk stratification 
in patients with AF [8, 28]. It may be hypothesized that 
these biomarkers may be helpful, not only in diagnostics, 
but also in prediction of future use or decision-making on 
introduction of interventional procedures, including car-
diac pacing, ablation and/or renal sympathetic denervation 
[29–37].
Several study limitations should be acknowledged. Since 
the vast majority of the current patients were at high risk 
of stroke or systemic thromboembolism, our findings could 
not be referred to low-risk AF patients or those receiving 
anticoagulant therapy, known to modify clot properties and 
decrease thrombin formation [38, 39]. The associations 
observed do not necessarily mean the cause–effect relation-
ship. Some of the relations tested in the current study, most 
probably due to relatively low number of patients and con-
founding factors present (comorbidities and cardiovascular 
disease risk factors), did not reach statistical significance. 
Determination of proinflammatory cytokines or oxidative 
stress markers was beyond the scope of this study. Molecular 
mechanisms behind the association of elevated GDF-15 with 
hypofibrinolysis in AF remain to be elucidated.
This study demonstrates that elevated GDF-15 and NT-
proBNP independently predict low plasma fibrinolytic 
potential measured in patients with AF off anticoagulation, 
while NT-proBNP is a key predictor of heightened thrombin 
formation in AF. The three key biomarkers measured in AF 
reflect various specific prothrombotic abnormalities, sug-
gesting that determination of the biomarkers might refine 
characterization of a hypercoagulable state in AF. This 
study provides data linking NT-proBNP and GDF-15 with 
prothrombotic blood alterations, which might support the 
concept of a value of the biomarkers in the estimation of 
stroke risk in AF.
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